Palmetto Issues Draft LCD for GenomeDx Prostate Cancer Genomic Classifier

Medicare contractor Palmetto GBA has issued a draft local coverage determination (LCD) for GenomeDx Biosciences’ Decipher Biopsy prostate cancer genomic classifier.  Decipher Biopsy, which utilizes a 22-biomarker expression signature, is intended to be used to determine which prostate cancer patients are likely to have a good outcome by being closely followed and can avoid more aggressive treatments.

Source: https://www.genomeweb.com/cancer/palmetto-issues-draft-lcd-genomedx-prostate-cancer-genomic-classifier?utm_medium=TrendMD&utm_campaign=0&utm_source=TrendMD&trendmd-shared=0